Navigation Links
Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
Date:2/4/2009

ROCKVILLE, Md. and NANTES, France, Feb. 4 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX) and Vivalis (NYSE Euronext: VLS) announced today the completion of a research license to use the Vivalis proprietary EB66(R) cell line, for the production of Novavax VLP based vaccines. Through this collaboration, Novavax intends to test the EB66(R) cell line for the production of VLP vaccines against several new potential viruses.

The EB66(R) cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics: (i) EB66(R) cells display long term genetic stability and immortality; (ii) they grow in suspension up to high cell densities in serum free medium; (iii) they can be scaled up for growth in large bioreactors for industrial productions; (iv) a biological master file (BMF) describing the history and sanitary status of the cell line is filed with the US Food and Drug Administration (FDA).

"Novavax is delighted to have the opportunity to evaluate the EB66(R) cell line for its potential use with our new VLP targets" stated Rahul Singhvi, Chief Executive Officer of Novavax. "This collaboration is consistent with our manufacturing strategy to use scalable cell culture solutions for production of recombinant VLP vaccines and increases our flexibility to design, develop and manufacture such vaccines to address significant unmet medical needs."

"Vivalis is very pleased to enter into this research license agreement with Novavax, one of the leading companies in the development of VLP based vaccines. Following the demonstration that the EB66(R) cell line is a promising substrate for the production of numerous viral vaccines such as flu or MVA based vaccines but also for the production of enhanced ADCC monoclonal antibody, we are delighted to start this program with Novavax to evaluate the us
'/>"/>

SOURCE Novavax
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... MA (PRWEB) November 26, 2014 ... collaboration company is proud to announce that Darren Suders ... and Sales. Darren will drive the partner ... positive customer experience. , Darren brings more ... has held key roles in channel operations, from policy ...
(Date:11/26/2014)... 25 novembre 2014 Theravalues Corporation est fier ... marché européen au salon Hi Europe 2014 (du ... ). Curcumine la plus biodisponible actuellement ... (non-cristalline) à des ingrédients approuvés par les règlements ... jaune présent dans la racine de curcuma ( ...
(Date:11/26/2014)... WARREN, N.J. , Nov. 25, 2014  Roka Bioscience, ... focused on providing advanced testing solutions for the detection of ... will present at the Piper Jaffray  26 th Annual ... conference will be held at The New York Palace in ... During this presentation, material information concerning the Company, its operations, ...
(Date:11/24/2014)... WASHINGTON , Nov. 24, 2014  Last ... G.K. Butterfield (D-NC) took a bold ... diseases by introducing the OPEN Act. Original co-sponsors ... Hastings (D-FL). The Act will incentivize drug makers ... life-threatening rare diseases and pediatric cancers, which opens ...
Breaking Biology Technology:SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
... , , COLUMBIA, Md., Sept. 16 Martek ... David M. Pernock to its Board of Directors. , ... extensive background in the commercialization of pharmaceutical products, having served from ... (GSK), one of the world,s leading healthcare companies. In his most ...
... HEIDELBERG, Germany, September 16 , ... Drug Targets in Wnt Pathway , ... antagonizes Wnt signalling"** is now available online in,Nature. , ... proteomics,platform was used to identify a small molecule which plays ...
Cached Biology Technology:American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4Martek Announces Addition to Its Board of Directors 2Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway 2
(Date:11/10/2014)... began appearing on U.S. store shelves in early 2010, ... since. The small packets can be tossed into a ... liquid or powder. The convenience, though, has come with ... researchers at Nationwide Children,s Hospital found that from 2012 ... 17,230 children younger than 6 years of age swallowing, ...
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
(Date:11/6/2014)... Fla. -- A groundbreaking paper from a team of ... understanding of how plants could adapt to and survive ... research, published in the latest issue of the journal ... chromatin (the complex of DNA and proteins) is organized ... so that some genes are turned on and others ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... the Center for the Neural Basis of Cognition (CNBC), ... University of Pittsburgh, have for the first time described ... are rewired on the fly allowing stimuli to be ... a paper in the January 2008 issue of Nature ...
... Suppressing a cellular cleanup-mechanism known as autophagy can accelerate ... degeneration. In an upcoming issue of Autophagy, scientists at ... first time that the opposite is true as well: ... prevented the age-dependent accumulation of cellular damage in neurons ...
... appear to have been influenced by RNA polymerase II. ... DNA into messenger-RNA (mRNA), which in turn is the ... is highly conserved through evolution, with many of its ... Single-cell organisms were already in existence 500 million ...
Cached Biology News:Neuronal circuits able to rewire on the fly to sharpen senses 2Aging gracefully requires taking out the trash 2Aging gracefully requires taking out the trash 3Evolution with a restricted number of genes 2